A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Trial Identifier: 2140-007
Sponsor: MSD
Start Date: July 2022
Primary Completion Date: April 2029
Study Completion Date: April 2029
Condition: Lymphoma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English
Protocol Plain Language Summary – English
Protocol Plain Language Summary – English

Trial Locations

Country Location
Canada, BC Victoria, BC, Canada, V8R 6V5
Canada, ON Toronto, ON, Canada, L6R3J7
Canada, QC Montreal, QC, Canada, H4J 1C5
Israel, N/A Jerusalem, N/A, Israel, 9112001
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Italy, Alessandria Alessandria, Italy, 15121
Italy, Lazio Roma, Lazio, Italy, 00168
Italy, Lombardia Milano, Lombardia, Italy, 20132
Italy, Sicilia Palermo, Sicilia, Italy, 90146
Italy, Toscana Firenze, Toscana, Italy, 50134
Korea, Republic of, Seoul Seoul, Korea, Republic of, 06351
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03080
Poland, Lodzkie Łódź, Lodzkie, Poland, 93-513
Poland, Mazowieckie Warszawa, Mazowieckie, Poland, 02-781
Poland, Pomorskie Gdańsk, Pomorskie, Poland, 80-214
Poland, Slaskie Gliwice, Slaskie, Poland, 44-101
Spain, Andalucia Sevilla, Andalucia, Spain, 41013
Spain, Barcelona L'Hospitalet del Llobregat, Barcelona, Spain, 08908
Spain, Madrid Madrid, Spain, 28040
Turkey, Ankara Ankara, Turkey, 06620
Turkey, Edirne Edirne, Turkey, 22030
Turkey, Istanbul stanbul, Istanbul, Turkey, 34214